Nicotinamide Riboside (NR)
Last reviewed
Nicotinamide Riboside (NR) is a specialized form of vitamin B3 that raises cellular NAD+ for energy and DNA repair. It directly suppresses mast cell degranulation via SIRT6 and inhibits MMP enzymes that degrade collagen in hEDS. ZebraThrive uses 500 mg daily of generic NR chloride with COA verification, chosen over NMN to avoid the 87% NMN counterfeit rate.
At a Glance
Daily Dose
500 mg daily (250 mg BID)
Key Benefits
How It Works
Nicotinamide Riboside (NR) is a cellular fuel that activates protective proteins called sirtuins.
For mast cells (MCAS): Groundbreaking 2022 research found that NR directly suppresses mast cell degranulation through the SIRT6 pathway. This reduces the release of histamine, tryptase, prostaglandins, and inflammatory cytokines like IL-6 and TNF-α. This mechanism makes NR a genuine mast cell stabilizer rather than just an anti-inflammatory.
For collagen (hEDS): NR activates SIRT1, which blocks the expression of MMP enzymes (collagen-destroying enzymes). It has been shown to reverse MMP-9 upregulation in tenocytes and fibroblasts. Additionally, it upregulates PLOD1 (lysyl hydroxylase), which is required for strong collagen crosslinking.
For mitochondria: NR consistently raises NAD+ levels, which restores mitochondrial function. This is particularly relevant for the multi-system fatigue and cellular dysfunction often seen across the triad.
What the Research Shows
NR directly inhibits the release of standard allergy mediators from human mast cells.
Preclinical (Theranostics, 2022)
Reduced histamine, tryptase, PGD2, and LTC4 production in human cord blood-derived mast cells.
Consistently doubles or raises NAD+ levels at therapeutic doses.
Human RCT (2019)
Dose-dependent and safe NAD+ increases established in multiple human cohorts.
High-dose safety trial (2024)
Demonstrated 5-fold NAD+ increase with no serious adverse events at massive doses.
Protects the extracellular matrix and restores energy production in connective tissue cells.
vEDS Cell Model (2025)
Improved mitochondrial health and reduced MMP activity in cells with vascular EDS mutations.
Activation of sirtuin pathways directly opposes the 'broken bucket' mechanism of collagen breakdown.
Addressing the Triad
Tailored benefits for complex conditions
The 2022 Kim study in Theranostics is the cleanest piece of mast cell mechanism work for any NAD+ precursor. NR suppressed degranulation in both mouse and human cord blood-derived mast cells, reduced histamine, TNF, IL-6, PGD2, and leukotrienes, and prevented anaphylaxis in mouse models - all through SIRT6, the same enzyme that vanishes when researchers knock it out. That's solid evidence: same mechanism from cells to whole animal. Several MCAS specialists have started using IV NR clinically as supportive treatment. We include NR for the mast cell mechanism, with mitochondrial support as a strong secondary benefit.
NR supports hEDS through the mitochondria-MMP axis. Dermal fibroblasts in hEDS show massive MMP-1 upregulation - about 53x normal - and mitochondrial dysfunction in fibroblasts is one of the upstream drivers. Cell studies in vascular EDS fibroblasts show NR can restore mitochondrial function and reduce MMP activity. Mouse work in Marfan syndrome showed NR reversed aortic aneurysm progression - a connective tissue benefit in a mouse model of a connective tissue disorder. The framing is plausible mechanism with consistent preclinical signals across multiple connective tissue models - exactly the kind of upstream support that complements the direct ECM-protective ingredients.
NR's mechanism for POTS centers on mitochondrial energy support for the chronic fatigue that frequently shadows POTS - many POTS patients also meet ME/CFS criteria. The blood pressure picture is reassuringly neutral at our dose: early data hinted at BP lowering, but replication studies showed essentially no effect at supplemental levels. So there's no orthostatic safety concern to watch for. NR sits in the protocol as a foundational mitochondrial support piece for the deep fatigue layer that comes with so much of the triad.
Why We Chose This Form
We use generic Nicotinamide Riboside Chloride at ≥99% purity, verified by Certificate of Analysis on every batch. NR is chemically unstable - it can degrade over time to nicotinamide, which actually inhibits the enzymes NR is supposed to support. So the single most important factor isn't the brand name, it's the analytical paperwork: identity confirmation, purity assay, and stability testing. We require full COA documentation for every batch - that's what determines whether the NR in the capsule is the molecule that does the work, not the marketing on the label.
Form Comparison
Unverified marketplace NR (no COA)
Up to 87% failure rate on label claims; counterfeit risk in untested suppliers
Generic NR chloride (≥99% purity, COA-verified)
Same molecule used in trials, verified by analytical paperwork; v7.8 spec
Safety & Interactions
Potential Side Effects
NR shows excellent safety even at extremely high doses (up to 3,000 mg). Occasional mild effects (<10%) include nausea, bloating, fatigue, or mild headaches. Long-term safety has been established in multi-month trials.
Drug Interactions
Blood pressure medications: Additive hypotension (~10 mmHg). Beta-blockers/Midodrine: May have opposing or additive effects on orthostatic symptoms. Warfarin: Monitor INR periodically. Diabetes medications: May affect glucose sensitivity.
Excipients to Avoid
- Fermentation-derived B-vitamins
- Unverified marketplace fillers
Safe Excipients
- Generic NR chloride (≥99% purity, COA-verified, fermentation-free)
- Methylation support if needed
A 10 mmHg systolic blood pressure reduction is documented. Patients on fludrocortisone or midodrine should monitor for reduced medication efficacy. Patients with methylation issues may benefit from concurrent methyl-donors (B12/Folate).
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Week 1 | 100 mg daily | Assess tolerance (AM only) |
| Week 2 | 125 mg twice daily | Building to target dose |
| Week 3 | 200 mg twice daily | Assessing energy and BP |
| Week 4+ | 250 mg twice daily | Full therapeutic dose (500 mg/day) |
"NAD+ elevation occurs within days. Functional improvements in energy or mast cell symptoms are highly variable and may take 4-12 weeks of consistent Use."
State of the Evidence
No clinical trials currently exist specifically in hEDS, POTS, or MCAS populations. While NR robustly elevates NAD+ (a biomarker), functional clinical outcomes in humans have been mixed in other populations. The mast cell stabilization property is currently supported by high-quality preclinical/lab data but requires MCAS patient validation.
- [1]NR suppresses mast cell degranulation via SIRT6PMID: 35547746
Kim et al. (2022)
- [2]Dose-dependent NAD+ increase; 300 mg safe and effectivePMID: 31278280
Conze et al. (2019)
- [3]NR restores mitochondrial function in vEDS cellsPMID: 40497944
Marcos-Ríos (2025)
- [4]~10 mmHg BP reduction at 1000 mg/dayPMID: 29599478
Martens (2018)
- [5]NR-SAFE: 3000 mg/day safe with 5-fold NAD+ increasePMID: 38016950
Berven (2024)
- [6]Busch et al., "SIRT1 reverses MMP-9 upregulation in tenocytes"PMID: 22689577
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .